REBYOTA™ for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study Study Summary

Clinical Trial Details

The purpose of this study is to better understand how well the medication REBYOTA is working to prevent recurrence of CDI (Clostridioides Difficile Infection) among adults following antibiotic treatment. The study also aims to understand patient-reported outcomes and health care utilization (e.g., doctors’ visits, and hospitalizations) after receiving REBYOTA.

REBYOTA prevents recurrence of CDI among adults following antibiotic treatment and this drug is approved by the U.S. Food and Drug Administration (FDA).

Study participants will complete paper diaries (collecting data, questionnaires, and outcomes).

Participation in this study will last for up to 24 weeks and participants will be compensated for their time.

Key Eligibility:

Men and women who are 18 years of age and older.
Have been diagnosed with CDI (Clostridioides Difficile Infection)

Detailed eligibility will be reviewed when contacting the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Mallory Ianelli, RN, BSN
(646) 962-4040
mai2016@med.cornell.edu

Primary Investigator(s)

Carl V. Crawford, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

2309026488

Status

Open to Enrollment

Age Group

Adult

Disease

Clostridium difficile infection